Case Report: A case of COL1A1 –PDGFB fusion uterine sarcoma at cervix and insights into the clinical management of rare uterine sarcoma
This article also serves as further clinical evidence of this disease, serving to increase clinical awareness of this rare sarcoma to avoid misdiagnosis. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 13, 2023 Category: Cancer & Oncology Source Type: research
Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups
Bull Cancer. 2023 Feb 28:S0007-4551(23)00050-4. doi: 10.1016/j.bulcan.2023.01.009. Online ahead of print.ABSTRACTUterine leiomyosarcomas represent the most common uterine sarcomas. The prognosis is poor with metastatic recurrence in more than half of the cases. The purpose of this review is to make French recommendations for the management of uterine leiomyosarcomas within the framework of the French Sarcoma Group - Bone Tumor Study Group (GSF-GETO)/NETSARC+ and Malignant Rare Gynecological Tumors (TMRG) networks in order to optimize their therapeutic management. The initial assessment includes a MRI with diffusion perfusi...
Source: Bulletin du Cancer - March 2, 2023 Category: Cancer & Oncology Authors: B érénice Collineau Catherine Genestie Sabrina Croce Pierre Meeus Anne Floquet Fr édéric Guyon Carmen Llacer-Moscardo Coriolan Lebreton Sophie Taieb Maud Toulmonde Jean Yves Blay Sylvie Bonvalot Isabelle Ray-Coquard Patricia Pautier Florence Duffaud Source Type: research
Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups
Bull Cancer. 2023 Feb 28:S0007-4551(23)00050-4. doi: 10.1016/j.bulcan.2023.01.009. Online ahead of print.ABSTRACTUterine leiomyosarcomas represent the most common uterine sarcomas. The prognosis is poor with metastatic recurrence in more than half of the cases. The purpose of this review is to make French recommendations for the management of uterine leiomyosarcomas within the framework of the French Sarcoma Group - Bone Tumor Study Group (GSF-GETO)/NETSARC+ and Malignant Rare Gynecological Tumors (TMRG) networks in order to optimize their therapeutic management. The initial assessment includes a MRI with diffusion perfusi...
Source: Bulletin du Cancer - March 2, 2023 Category: Cancer & Oncology Authors: B érénice Collineau Catherine Genestie Sabrina Croce Pierre Meeus Anne Floquet Fr édéric Guyon Carmen Llacer-Moscardo Coriolan Lebreton Sophie Taieb Maud Toulmonde Jean Yves Blay Sylvie Bonvalot Isabelle Ray-Coquard Patricia Pautier Florence Duffaud Source Type: research
Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes
Gynecol Oncol. 2023 Feb 24;171:95-105. doi: 10.1016/j.ygyno.2023.02.009. Online ahead of print.ABSTRACTEndometrial stromal tumors (EST) are uterine mesenchymal tumors, which histologically resemble endometrial stroma of the functioning endometrium. The majority of EST are malignant tumors classified as low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS). Overall, ESTs are rare malignancies, with an annual incidence of approximately 0.30 per 100'000 women, mainly affecting peri- or postmenopausal women. The most common genetic alteration...
Source: Gynecologic Oncology - February 26, 2023 Category: Cancer & Oncology Authors: Angiolo Gadducci Francesco Multinu Luigi Antonio De Vitis Stefania Cosio Silvestro Carinelli Giovanni Damiano Aletti Source Type: research
Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes
Gynecol Oncol. 2023 Feb 24;171:95-105. doi: 10.1016/j.ygyno.2023.02.009. Online ahead of print.ABSTRACTEndometrial stromal tumors (EST) are uterine mesenchymal tumors, which histologically resemble endometrial stroma of the functioning endometrium. The majority of EST are malignant tumors classified as low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS). Overall, ESTs are rare malignancies, with an annual incidence of approximately 0.30 per 100'000 women, mainly affecting peri- or postmenopausal women. The most common genetic alteration...
Source: Gynecologic Oncology - February 26, 2023 Category: Cancer & Oncology Authors: Angiolo Gadducci Francesco Multinu Luigi Antonio De Vitis Stefania Cosio Silvestro Carinelli Giovanni Damiano Aletti Source Type: research
Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes
Gynecol Oncol. 2023 Feb 24;171:95-105. doi: 10.1016/j.ygyno.2023.02.009. Online ahead of print.ABSTRACTEndometrial stromal tumors (EST) are uterine mesenchymal tumors, which histologically resemble endometrial stroma of the functioning endometrium. The majority of EST are malignant tumors classified as low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS). Overall, ESTs are rare malignancies, with an annual incidence of approximately 0.30 per 100'000 women, mainly affecting peri- or postmenopausal women. The most common genetic alteration...
Source: Gynecologic Oncology - February 26, 2023 Category: Cancer & Oncology Authors: Angiolo Gadducci Francesco Multinu Luigi Antonio De Vitis Stefania Cosio Silvestro Carinelli Giovanni Damiano Aletti Source Type: research
Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes
Gynecol Oncol. 2023 Feb 24;171:95-105. doi: 10.1016/j.ygyno.2023.02.009. Online ahead of print.ABSTRACTEndometrial stromal tumors (EST) are uterine mesenchymal tumors, which histologically resemble endometrial stroma of the functioning endometrium. The majority of EST are malignant tumors classified as low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS). Overall, ESTs are rare malignancies, with an annual incidence of approximately 0.30 per 100'000 women, mainly affecting peri- or postmenopausal women. The most common genetic alteration...
Source: Gynecologic Oncology - February 26, 2023 Category: Cancer & Oncology Authors: Angiolo Gadducci Francesco Multinu Luigi Antonio De Vitis Stefania Cosio Silvestro Carinelli Giovanni Damiano Aletti Source Type: research
Endometrial carcinosarcoma: a poor prognosis debut with favourable therapeutic outcome
We report a case of a 73-year-old patient who presented postmenopausal abnormal uterine bleeding and was diagnosed with ECS. A non-conventional treatment approach was conducted with favourable oncological outcomes.PMID:36819811 | PMC:PMC9934871 | DOI:10.3332/ecancer.2022.1472 (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - February 23, 2023 Category: Cancer & Oncology Authors: Mar ía Fernanda Toro-Wills Angelina Álvarez-Londoño Abraham Hern ández-Blanquisett Fernando Salas Marquez Mar ía Cristina Martínez-Ávila Source Type: research
